TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Suppression of flare area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Days with exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total oestrone (tE1) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Non-SHBG-bound testosterone (NST) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Median time to treatment failure
Endpoint domain: Mortality/survival
Primary endpoint: Number of recurrences
Endpoint domain: Mortality/survival
Primary endpoint: VAT estimation by DXA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: antipyretic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tobacco use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: multidrug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of vasomotor symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BDI score increase
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severity of menopause-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of negative symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abortion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: TCM symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adjusted prevalence of any condom use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted prevalence of answering 10/12 HIV knowledge questions correctly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intimate partner violence prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean maximum plasma concentration of tramadol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean cumulative area under the plasma concentration-time curve of tramadol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median time to maximum plasma concentration of tramadol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor impairment prediction accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean paresthesia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: care burden ratings
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: GFR estimation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time in therapeutic range (TTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: communication effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MIF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: impaired performance status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percent V pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean distance between the centre of the chignon and the flexion point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delegation of decision making
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Patients no longer meeting criteria for fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients painfree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: olfactory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of hip subluxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency of hip problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Need for treatment of hip subluxation/dislocation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: postoperative kneeling discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: decreased skin sensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: femoral tunnel widening
Endpoint domain: Adverse events/effects
Primary endpoint: Mean reduction in IOP from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving IOPs at or below 17 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in eosinophil counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in allergic conjunctivitis and allergic rhinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean blood loss during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bladder neck contractures
Endpoint domain: Adverse events/effects
Primary endpoint: average pain score during biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients with pain score > 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥1-point improvement in Investigator GLSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WSS of None or Mild
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target vessel revascularization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Primary composite clinical endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death rate in 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Length of stay in ICU (days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: APACHEII score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase of systolic blood pressure after intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient-controlled epidural analgesia volume consumed per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor block (Bromage score <5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pin tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: External fixation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Range of motion (ROM) of knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patient satisfaction with telemedicine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Consultation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Travel cost per visit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Completed suicide incidence
Endpoint domain: Mortality/survival
Primary endpoint: IBDQ-B score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: relief of nicotine withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of radiologic damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Headache intensity and duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in HbA₁c
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fasting plasma glucose (FPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: final mean daily insulin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of bile duct stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic progression of spinal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean per-occasion alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum per-occasion alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage of successfully treated weeks per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of limited activity days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Estimated increase in asthma quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: LDL-cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of ampules of hMG required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attenuation of craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in inhaled corticosteroid dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum neuromuscular blocking effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety-state reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: recovery rates
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intolerance to SFGC
Endpoint domain: Adverse events/effects
Primary endpoint: Serious allergic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: LDH concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle volume of tibialis anterior and gastrocnemius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean visual acuity in the amblyopic eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean interocular acuity difference (IOD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vagal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival of patients
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of MACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of analgesia at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional outcome at 36 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FEV1 percent predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: blood eosinophil levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sputum eosinophil levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: DNA rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: High end-state functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: itch area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alpha-linolenic acid content in non-esterified fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: help-seeking intentions
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Normalization of alanine aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatitis B e antigen clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatitis B virus DNA clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term intestinal eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of intestinal ESBL-EC/KP burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Altered intestinal microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of more than 50% in monthly headache frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean distance between file tip and radiographic apex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levodopa-induced dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Myocardial-free carnitine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caffeine T(lim)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RPE at 90 s
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarker level of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Association of Cystatin C levels with Neurocognitive Impairment (NCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: worsening of ascites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative number of large‐volume paracenteses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to obtain satisfactory analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall confidence in performing DRE
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: OHIPG-14 total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: XQ Part 1 dysphagia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: halitosis organoleptic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum vitamin A concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum vitamin E concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fecal amounts of total Lactobacilli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal amounts of heterofermentative Lactobacilli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal amounts of total Bifidobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in K(i)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of phlebitis
Endpoint domain: Adverse events/effects
Primary endpoint: Nuclear density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Risk of Mortality score
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in sound knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in good attitude related to HIV
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in high substance risk behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total PAEE change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum applied force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum force gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total applied force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: angiographical lesion restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinical restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma triacylglycerol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma FVII:c levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time required for administration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Emotional role functioning discrepancies
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical role functioning discrepancies
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Social functioning discrepancies
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Bodily pain discrepancies
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Response rates using the novel index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hSLEDAI score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BILAG score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe pain of ≥ 50 mm on the VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gas retention in the small bowel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Residual gas retention in the large bowel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Efficacy of aromatase inhibitors in breast cancer treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Parasympathetic recovery from exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hematoma rate
Endpoint domain: Adverse events/effects
Primary endpoint: Force applied during intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loperamide plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pupil size changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Normalization of diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of hyperuricemia
Endpoint domain: Adverse events/effects
Primary endpoint: Major macrovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major clinical microvascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bedside falls rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first bedside fall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal Epo excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: sustained reduction of corticosteroid dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete reduction of corticosteroid dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour pain relief response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of headache recurrence up to 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean training intensity (Wt/Wpeak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak work rate after training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in plasma lactate concentration (DeltaL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective preference for AR-coated lenses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in overall night vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sealing pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic interaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EDITS index scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Palsy of the recurrent laryngeal nerve
Endpoint domain: Adverse events/effects
Primary endpoint: Hypoparathyroidism
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrent goitres
Endpoint domain: Adverse events/effects
Primary endpoint: Median stool output/kg body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intake of oral rehydration solution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Need for unscheduled intravenous acetate solution
Endpoint domain: Adverse events/effects